Table 3.

Uni- and multivariate analysis

Variable	Ipsilateral breast tumor recurrence				Locoregional recurrence
	Univariate		Multivariate		Univariate		Multivariate
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
≤ 40 yr	1.0		1.0		1.0		1.0
> 40 yr	0.8 (0.3-1.9)	0.59	0.9 (0.4-2.3)	0.80	0.8 (0.4-1.6)	0.49	0.7 (0.3-1.6)	0.41
Luminal A	1.0		1.0		1.0		1.0
Luminal B1	3.6 (0.7-17.6)	0.12	3.1 (0.6-16.5)	0.20	2.7 (0.6-12.2)	0.19	1.9 (0.4-9.3)	0.43
Luminal B2	3.2 (0.8-12.5)	0.09	3.3 (0.8-13.8)	0.10	3.5 (1.1-11.3)	0.03	3.4 (1.0-11.1)	0.04
HER2 (T+)	2.7 (0.3-26.3)	0.38	1.8 (0.2-18.9)	0.62	2.1 (0.2-19.2)	0.50	1.5 (0.2-14.0)	0.74
HER2 (T–)	4.2 (0.8-20.8)	0.08	4.2 (0.8-22.6)	0.04	6.5 (1.8-23.2)	< 0.01	7.6 (2.0-28.9)	< 0.01
Triple negative	6.5 (1.7-23.8)	< 0.01	6.9 (1.7-28.1)	< 0.01	7.0 (2.3-21.6)	< 0.01	8.1 (2.5-26.6)	< 0.01
Well-moderate	1.0		1.0		1.0		1.0
Poor	2.4 (1.1-5.4)	0.03	1.9 (0.7-5.2)	0.19	2.3 (1.2-4.4)	0.01	1.5 (0.7-3.3)	0.34
Non-pCR	1.0		1.0		1.0		1.0
pCR	1.0 (0.3-2.9)	0.99	1.8 (0.5-7.3)	0.39	0.9 (0.3-2.2)	0.78	1.3 (0.4-4.1)	0.65
RM (–)	1.0		1.0		1.0		1.0
Close or RM (+)	1.3 (0.4-4.4)	0.65	1.4 (0.4-5.4)	0.59	1.7 (0.6-4.3)	0.30	2.0 (0.7-5.5)	0.21
cT1-2	1.0		1.0		1.0		1.0
cT3-4	8.8 (4.1-19.1)	< 0.01	8.4 (3.8-18.9)	< 0.01	5.4 (2.8-10.6)	< 0.01	5.0 (2.5-10.1)	< 0.01
cN0-1	1.0		1.0		1.0		1.0
cN2-3	1.2 (0.5-2.5)	0.71	0.6 (0.3-1.5)	0.29	1.8 (0.9-3.4)	0.09	1.2 (0.6-2.4)	0.69
ypT0-1	1.0		1.0		1.0		1.0
ypT2-3	1.6 (0.7-3.5)	0.26	1.4 (0.5-3.4)	0.52	1.7 (0.9-3.3)	0.11	1.5 (0.7-3.2)	0.32
ypN0-1	1.0		1.0		1.0		1.0
ypN2-3	1.4 (0.6-3.1)	0.47	2.0 (0.8-5.3)	0.16	1.7 (0.9-3.4)	0.11	2.1 (0.9-4.6)	0.06

OR, odds ratio; CI, confidence interval; HR, hazard ratio; HER2 (T+) , HER2 with trastuzumab; HER2 (T–), HER2 without trastuzumab; pCR, pathologic complete response; RM (–), negative resection margin; RM (+), positive resection margin.